Retireful LLC Reduces Position in Natera, Inc. $NTRA

Retireful LLC decreased its holdings in Natera, Inc. (NASDAQ:NTRA) by 25.4% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 5,489 shares of the medical research company’s stock after selling 1,872 shares during the quarter. Retireful LLC’s holdings in Natera were worth $927,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in shares of Natera by 0.6% during the first quarter. Vanguard Group Inc. now owns 12,393,827 shares of the medical research company’s stock valued at $1,752,611,000 after purchasing an additional 77,357 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in Natera by 56.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company’s stock worth $1,490,144,000 after purchasing an additional 3,795,315 shares during the period. JPMorgan Chase & Co. raised its stake in Natera by 9.9% during the 1st quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company’s stock valued at $1,041,055,000 after buying an additional 660,538 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of Natera by 13.7% during the 1st quarter. Invesco Ltd. now owns 2,035,979 shares of the medical research company’s stock valued at $287,908,000 after buying an additional 245,719 shares during the period. Finally, Maverick Capital Ltd. lifted its holdings in shares of Natera by 19.7% during the 1st quarter. Maverick Capital Ltd. now owns 1,634,769 shares of the medical research company’s stock valued at $231,173,000 after buying an additional 268,715 shares during the period. Institutional investors own 99.90% of the company’s stock.

Natera Trading Down 5.2%

Natera stock opened at $163.91 on Thursday. Natera, Inc. has a 12-month low of $117.27 and a 12-month high of $183.00. The firm has a market capitalization of $22.50 billion, a price-to-earnings ratio of -85.82 and a beta of 1.68. The firm has a 50 day moving average of $157.99 and a 200 day moving average of $155.63.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The firm had revenue of $546.60 million for the quarter, compared to analysts’ expectations of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. Natera’s revenue for the quarter was up 32.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. On average, analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Insiders Place Their Bets

In related news, insider John Fesko sold 678 shares of the stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $155.46, for a total transaction of $105,401.88. Following the completion of the sale, the insider owned 152,747 shares in the company, valued at approximately $23,746,048.62. This trade represents a 0.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Solomon Moshkevich sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $166.62, for a total value of $499,860.00. Following the completion of the transaction, the insider directly owned 120,859 shares in the company, valued at approximately $20,137,526.58. This represents a 2.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 56,423 shares of company stock worth $8,459,656 in the last three months. 5.63% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Barclays reiterated an “overweight” rating and set a $210.00 price objective (up previously from $190.00) on shares of Natera in a research report on Friday, August 8th. Stephens restated an “overweight” rating and set a $183.00 price target on shares of Natera in a research note on Friday, August 15th. Piper Sandler reaffirmed an “overweight” rating and set a $220.00 price target (up previously from $210.00) on shares of Natera in a research report on Monday, August 11th. Wells Fargo & Company began coverage on shares of Natera in a report on Monday. They issued an “equal weight” rating and a $175.00 price objective on the stock. Finally, Morgan Stanley restated an “overweight” rating and set a $195.00 target price on shares of Natera in a research report on Sunday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $192.88.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.